Class Action Lawsuit - Levi & Korsinsky, LLP notifies investors in Applied Therapeutics, Inc (NASDAQ: APLT) of a class action securities lawsuit seeking to recover losses for investors affected by alleged securities fraud between January 3, 2024 and December 2, 2024 [1] Case Details - Applied Therapeutics received a Complete Response Letter (CRL) from the FDA on November 27, 2024 for its New Drug Application (NDA) for govorestat, citing deficiencies in the clinical application [2] - Following the CRL announcement, Applied Therapeutics' stock price declined from $10 21 per share on November 26, 2024 to $8 57 per share on November 27, 2024, and further to $2 03 on November 29, 2024 and $1 75 per share on December 2, 2024, a total decline of more than 80% [2] - On December 2, 2024, Applied Therapeutics disclosed a "warning letter" from the FDA regarding clinical trial issues, causing the stock price to fall further to $1 69 per share on December 3, 2024, $1 38 per share on December 4, 2024, and $1 29 per share on December 5, 2024 [2] Next Steps for Investors - Investors who suffered losses in Applied Therapeutics during the relevant time frame have until February 18, 2025 to request the Court appoint them as lead plaintiff [3] - Class members may be entitled to compensation without payment of any out-of-pocket costs or fees [3] Levi & Korsinsky Expertise - Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders over the past 20 years and has a team of over 70 employees [4] - The firm has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States for seven consecutive years [4]

NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Applied Therapeutics investors who were adversely affected by alleged securities fraud between January 3, 2024 and December 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra ...

NEW YORK, Jan. 6, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. (NASDAQ: APLT) between January 3, 2024 and December 2, 2024, both dates inclusive (the "Class Period"), of the important February 18, 2025 lead plaintiff deadline.So what: If you purchased Applied Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

Class Action Lawsuit Overview - The law firm Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against Applied Therapeutics Inc (NASDAQ: APLT) for securities purchased or acquired between January 3 2024 and December 2 2024 [1] - The lawsuit alleges violations of the Securities Exchange Act of 1934 by Applied Therapeutics and certain top executives [1] - Investors who suffered substantial losses can seek appointment as lead plaintiff by February 18 2025 [1] Case Allegations - Applied Therapeutics is a clinical-stage biopharmaceutical company developing drug candidates for rare diseases [2] - The company submitted a New Drug Application (NDA) to the FDA for govorestat to treat Classic Galactosemia on January 3 2024 [2] - The lawsuit claims that Applied Therapeutics made false or misleading statements and failed to disclose non-adherence to trial protocols and good clinical practices, risking FDA rejection of trial data [3] FDA Response and Stock Impact - On November 27 2024, the FDA issued a Complete Response Letter for the NDA, stating it could not approve the application in its current form due to deficiencies in the clinical application [4] - Following this news, Applied Therapeutics stock price fell more than 80% over three trading sessions [4] - On December 2 2024, the company disclosed an FDA warning regarding issues with electronic data capture and a dosing error in the study, leading to a further 26% drop in stock price over three trading sessions [5] Lead Plaintiff Process - Investors who purchased or acquired Applied Therapeutics securities during the Class Period can seek appointment as lead plaintiff under the Private Securities Litigation Reform Act of 1995 [6] - The lead plaintiff represents all class members and selects the law firm to litigate the case [6] - Serving as lead plaintiff is not required to share in any potential future recovery [6] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, ranked 1 in ISS Securities Class Action Services for six of the last ten years [7] - The firm has recovered $6 6 billion for investors in securities-related class action cases, including the largest recovery ever of $7 2 billion in the Enron Corp case [7]

NEW YORK, Jan. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT).Shareholders who purchased shares of APLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/applied-therapeutics-inc-loss-submission-form/?id=120460&from=4 CLASS PERIOD: J ...

RADNOR, Pa., Jan. 5, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Applied Therapeutics, Inc. ("Applied Therapeutics") (NASDAQ: APLT) on behalf of those who purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024, and December 2, 2024, inclusive (the "Class Period"). The lead plaintif ...

NEW YORK, Jan. 05, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Applied Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc. Investors have until February 18, 2025, to a ...

Core Viewpoint - A securities class action lawsuit has been filed against Applied Therapeutics, Inc. for alleged misconduct related to its drug candidate, govorestat, during the Class Period from January 3, 2024, to December 2, 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who acquired Applied Therapeutics securities during the specified Class Period [1]. - The lead plaintiff deadline for the lawsuit is set for February 18, 2025 [1][4]. Group 2: Allegations Against Defendants - The complaint alleges that the defendants made false and misleading statements and failed to disclose that Applied Therapeutics was not following trial protocols and good clinical practices for govorestat [3]. - This alleged misconduct created a significant risk that the trial data would be rejected by the FDA in the context of a New Drug Application [3]. Group 3: Lead Plaintiff Process - Investors in Applied Therapeutics can seek to be appointed as a lead plaintiff representative of the class by the deadline of February 18, 2025, or may choose to remain an absent class member [4]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or small group of investors with the largest financial interest [4].

NEW YORK, Dec. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT).Shareholders who purchased shares of APLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/applied-therapeutics-inc-loss-submission-form/?id=118954&from=4CLASS PERIOD: J ...

NEW YORK, Dec. 28, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Applied Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc. Investors have until February 18, 2025, to a ...